Quanterix, which makes next-generation protein detection tests for clinical research, announced terms for its IPO on Monday.
The Lexington, MA-based company plans to raise $50 million by offering 3.3 million shares at a price range of $14 to $16. Insiders intend to purchase $30 million worth of shares in the offering. At the midpoint of the proposed range, Quanterix would command a fully diluted market value of $325 million.
Quanterix was founded in 2007 and booked $23 million in sales for the 12 months ended September 30, 2017. It plans to list on the Nasdaq under the symbol QTRX. J.P. Morgan and Leerink Partners are the joint bookrunners on the deal. It is expected to price during the week of December 4, 2017.
